The pursuit of longevity has long fascinated humans, with the quest for a longer, healthier life driving innovation across various fields. In India, this pursuit has given rise to a burgeoning longevity science sector, with startups and research institutions alike exploring new frontiers in aging biology. One such entity making waves in this space is Decode Age, a Bengaluru-based company that has developed gut microbiome tests and supplements designed to promote healthy aging.
The company's approach is rooted in the understanding that the gut microbiome plays a crucial role in overall health, influencing everything from digestion and metabolism to immune function and even cognitive health. By analyzing an individual's gut microbiome, Decode Age aims to provide personalized insights and recommendations for improving gut health, thereby supporting overall well-being and potentially even increasing lifespan. This innovative approach has already garnered significant attention and investment, with the company securing ₹14.48 crore in pre-Series A funding in December 2025.
The investment, led by Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, underscores the growing interest in India's longevity science sector. This trend is not unique to India, as the global longevity market is expected to experience significant growth in the coming years, driven by increasing awareness of the importance of preventive healthcare and the potential of emerging technologies like genomics and artificial intelligence to transform our understanding of aging.
For India, the growth of the longevity science sector presents a unique opportunity. On one hand, it allows the country to leverage its existing strengths in biotechnology and pharmaceuticals to develop innovative solutions for the global market. On the other hand, it enables Indian researchers and entrepreneurs to address some of the country's most pressing health challenges, such as the rising burden of non-communicable diseases, by developing targeted, personalized interventions.
Decode Age's collaboration with the Longevity India Initiative and the Indian Institute of Science (IISc) is a testament to this potential. By bringing together academic research, clinical expertise, and entrepreneurial spirit, such partnerships can accelerate the development of new therapies and products, ultimately benefiting not just the Indian population but also contributing to global advancements in longevity science.
However, as with any emerging field, there are also challenges to navigate. Regulatory frameworks, for instance, will need to evolve to keep pace with the rapid advancements in longevity science, ensuring that innovations are safely and ethically brought to market. Additionally, addressing issues of accessibility and affordability will be crucial, lest these cutting-edge technologies exacerbate existing health disparities.
Looking ahead, the future of India's longevity science sector appears promising. With continued investment, collaboration, and a focus on addressing the unique health challenges of the Indian population, entities like Decode Age are poised to make significant contributions, both domestically and internationally. As the global community continues its quest for a longer, healthier life, India's role in this journey is likely to grow, driven by innovation, entrepreneurship, and a deepening understanding of the complex interplay between biology, technology, and human well-being.
